Lifestyle and Weight Management Services

The NHS has a range of advice and tools to help with weight loss which you can find here. This includes advice and tools on how to get started with weight loss, information on Type 2 diabetes and a download to the free NHS Weight Loss Plan. 

You can find our patient weight management webpage here. 

Useful documents

Important notice

Please note that all these online documents are the only versions that are maintained. Printed or offline versions should be viewed as ‘uncontrolled’ and may not necessarily contain the latest updates and amendments, including updated hyperlinks.

Any feedback you have on the clinical pathways on this website would be greatly appreciated. Please send your feedback, as well as clinical pathway queries, to nhsbsolicb.clinicalpathways@nhs.net.

Please note that nhsbsolicb.clinicalpathways@nhs.net is not for personal appointment queries. If you have questions or concerns regarding your personal appointment, please contact the healthcare provider you have been referred to or return to your original referrer for assistance.

Tirzepatide

About tirzepatide

  • Tirzepatide works by supressing appetite centres in the brain that control gut hormones. It decreases the appetite and slows the movement of food passing through the body, making you feel fuller for longer.
  • Clinical trials have shown tirzepatide can help people living with obesity lose up 20% of their starting body weight, depending on the dose and accompanying diet and lifestyle support.
  • Tirzepatide can only be prescribed by a healthcare professional alongside programmes which support people to lose weight and live healthier lives by making changes to their diet and physical activity
  • Tirzepatide comes as an injection, which can be self-administered once a week.

You can read the updated NICE guidelines for tirzepatide here. 

FAQ's

  • People in England over the age of 18 who are living with obesity and another weight-related health issue will be able to access the weight loss drug tirzepatide through specialist weight management services (SWMS) from spring 2025. In primary care services, access will begin in summer 2025
  • Tirzepatide is currently prescribed for the treatment of type 2 diabetes but will now also be available for weight loss purposes.

 

The ICB is rolling out prescribing Tirzepatide via primary care services to three cohorts of patients over three years (2025 – 2028) in line with NHS England funding and interim commissioning guidance.

 

Eligibility criteria differs across the cohorts as follows, and eligible patients are identified via their GP records:

 

Cohort 1 – Patients must have a body mass index (BMI) of 40 or higher and four or more of the following comorbidities: hypertension, dyslipideamia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus

 

Cohort 2 - Patients must have a body mass index (BMI) between 35 and 39.9 and four or more of the following comorbidities: hypertension, dyslipideamia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus

 

Cohort 3 - Patients must have a body mass index (BMI) of 40 or higher and three or more of the following comorbidities: hypertension, dyslipideamia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus.

 

Please note: The BMI threshold is reduced by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean ethnic backgrounds.

 

  • Introducing this new treatment to NICE’s estimated 3.4 million eligible patients requires the NHS in England to develop a completely new service for primary care and many healthcare professionals will need to be trained to deliver it.  A staged approach will help manage demand on existing healthcare services. This allows the safe prescribing of tirzepatide and the appropriate support for patients.
  • Tirzepatide will not immediately be available and will not be accessible to everyone who wishes to use it. Initially, tirzepatide will only be available on the NHS to those expected to benefit the most. People who are eligible for tirzepatide through primary care services should only expect to start to get access by mid 2025.

  • A staged approach to service rollout within primary care means NHS in England will manage the flow of patients to the health system so it does not become overwhelmed.
  • This approach will ensure the service is delivered safely and that the NHS in England is able to plan for an increase in service demand, whilst building specific skills and knowledge within the workforce.

  • Patients can continue taking tirzepatide if they are prescribed it to manage their diabetes.
  • If patients are using tirzepatide they have acquired privately, they may be able to access the medication through an NHS prescription if they meet the NICE and NHS qualifying criteria. More information about this will be made available in the new year.

  • Tirzepatide might not be suitable for everyone and not everyone who meets the eligibility criteria will want to use it to support their weight loss. A healthcare professional will discuss the most appropriate care and support, based on individual patient’s need. This could include behavioural support programmes, medical options including prescribing or bariatric surgery.

  • A healthcare professional will determine if it is appropriate for you to receive tirzepatide as part of your care in a different care setting (for example, through primary care).

  • Any patient prescribed tirzepatide must participate in the specifically designed ‘wraparound’ care required by NICE guidance. This focuses on diet, nutrition and increasing physical activity. As NHS England develops the service, it will provide more details of the wraparound support offer for patients who qualify. Patients cannot be prescribed tirzepatide if they do not wish to undertake the wraparound care support.

  • Normal prescription charges will apply unless you are entitled to free NHS prescriptions (for example, because you have a medical exemption certificate).